Oracle announces it is acquiring Relsys International, a company that provides drug safety and risk management solutions with advanced analytics. Acquiring Relsys will position Oracle to deliver a suite of software applications specifically designed for the growing field of health care IT, including clinical development, post-market surveillance and patient care apps.
Oracle
announced on March 23 an agreement to acquire Relsys International, which
offers drug safety and risk management solutions with advanced analytics for
the health sciences industry.
Relsys offers solutions for event reporting, risk management and data
analysis in the pharmaceutical and biotechnology arenas. By acquiring Relsys,
Oracle will gain the ability to deliver software applications for drug safety
in every part of the clinical development chain as well as post-market
surveillance and patient care.
The deal is expected to close in the first half of 2009; financial details
of the transaction were not disclosed by either Oracle or Relsys, both of which
will continue to operate independently until the deal is finalized.
"The health sciences industry is increasing investments in software
that provide greater transparency into drug safety and help improve the overall
safety of therapies," Neil de Crescenzo, senior vice president and general
manager of Oracle Health Sciences, said in a statement. By acquiring Relsys,
Oracle will be positioned to deliver "a comprehensive software solution
that enables our vision of integrated safety and risk management supported by
advanced analytics."
IT companies have been exploring ways to penetrate the potentially lucrative
health care market. On March 5,
Google
announced that users of its
Google
Health solution would be able to share their medical records and personal
health information with trusted contacts online.
In June 2008, Oracle created its Health Sciences Global Business Unit,
designed to provide software application to the health-services industry. Its
software applications in the health care space include Oracle Clinical, Oracle
Remote Data Capture, Oracle Adverse Event Reporting System, and Oracle's Siebel
Clinical Trial Management System.
Despite the recession,
Oracle
has performed steadily, with third-quarter fiscal 2009 earnings per share up 3
percent over the same quarter last year. It has also released a wave of new
products designed to make inroads in separate areas of the enterprise.
In recent weeks,
Oracle
has seemed close to acquiring SMB server virtualization specialist Virtual Iron
Software, according to an analyst and a number of Web sites, in order to
better position itself to compete with VMware and Citrix Systems in the area of
virtualization products.
On March 9,
the
company released Oracle Sourcing On Demand, a SAAS (software as a service)
solution designed to make supply chain management more efficient and
cost-effective.
And on Feb. 4, in its first acquisition of 2009,
Oracle
purchased mValent, which offered configuration management solutions that could
be used to provide efficiencies within Oracle Enterprise Manager.